临床-超声评分系统筛查胎盘植入谱系的系统评价与Meta分析
该系统评价与Meta分析检索1982年10月至2022年10月的文献,纳入12项队列研究和2项病例对照研究共1630例接受临床-超声评分筛查胎盘植入谱系的患者。作者认为临床-超声评分系统有助于产前筛查,并建议标准化评估和前瞻性记录相关指标。
要点
- 临床-超声评分系统合并敏感度0.68(95%CI 0.53-0.80),合并特异度0.88(95%CI 0.68-0.96)。
- 作者认为最具预测价值的筛查变量为胎盘床下方透明带消失、子宫下段胎盘附着及胎盘陷窝。
核心结论
- 临床-超声评分系统可有助于产前筛查分娩时存在胎盘植入谱系风险的患者。
- 作者建议不仅应采用严格的超声标准评估胎盘位置、检查时孕中期晚段孕龄及与胎盘植入谱系相关的超声标志物,还应标准化评估。
- 作者建议前瞻性记录数值敏感度、特异度、阴性预测值、阳性预测值、阴性似然比和阳性似然比,以评估其在不同设置中的准确性,并应在分娩时核实验前概率。
- 作者推荐最具预测价值的筛查变量为:胎盘床下方透明带消失、子宫下段胎盘附着及胎盘陷窝。
研究设计与样本
- 系统评价与Meta分析,检索PubMed/MEDLINE、Google Scholar和Embase从1982年10月至2022年10月的文献。
- 纳入标准为观察性研究,提供从中孕期开始应用临床-超声联合评分系统对胎盘植入谱系进行产前评估的数据。
- 共纳入12项队列研究和2项病例对照研究,包括1630例经临床-超声评分筛查胎盘植入谱系的患者。
- 研究方案注册于PROSPERO(CRD42022332486),由2名独立评价者按预先设计的方案评估研究特征。
主要发现
- 602例(36.9%)报告了胎盘植入谱系诊断,其中547例(90.9%)描述了术中表现和/或组织病理学数据。
- 各研究间报告的敏感度、特异度及用于识别分娩时高概率胎盘植入谱系患者的阈值存在较大差异。
- 单项超声评分的曲线下面积汇总范围从胎盘下富血供的最低0.85,到胎盘位于子宫下段、子宫肌层变薄及胎盘陷窝的0.91,以及透明带消失的0.95。
- 仅4项研究将胎盘膨出纳入其超声评分系统,因此未对该评分进行Meta分析。
关键数值与推荐
- 作者推荐最具预测价值的筛查变量为:胎盘床下方透明带消失、子宫下段胎盘附着及胎盘陷窝。
临床怎么用
- 临床-超声评分系统可有助于产前筛查分娩时存在胎盘植入谱系风险的患者。
- 作者建议采用严格的超声标准评估胎盘位置、检查时孕中期晚段孕龄及与胎盘植入谱系相关的超声标志物,并进行标准化评估。
- 作者建议前瞻性记录数值敏感度、特异度、阴性预测值、阳性预测值、阴性似然比和阳性似然比,以评估其在不同设置中的准确性,并应在分娩时核实验前概率。
局限性
- 各研究间报告的敏感度、特异度及用于识别分娩时高概率胎盘植入谱系患者的阈值存在较大差异。
- 仅4项研究将胎盘膨出纳入其超声评分系统,因此未对该评分进行Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical-sonographic scoring systems combining clinical features and ultrasound imaging markers have been proposed for the screening of placenta accreta spectrum, but their usefulness in different settings remains limited. This study aimed to assess and compare different clinical-sonographic score systems applied from mid-pregnancy for the prenatal evaluation of patients at risk of placenta accreta spectrum at birth. DATA SOURCES: PubMed/MEDLINE, Google Scholar, and Embase were searched between October 1982 and October 2022 to identify eligible studies. STUDY ELIGIBILITY CRITERIA: Observational studies providing data on the use of a combined clinical-ultrasound score system applied from mid-pregnancy for the prenatal evaluation of placenta accreta spectrum were included. METHODS: Study characteristics were evaluated by 2 independent reviewers using a predesigned protocol registered on PROSPERO (CRD42022332486). Heterogeneity among studies was analyzed with Cochran's Q-test and I2 statistics. Statistical heterogeneity was quantified by estimating the variance between the studies using I2 statistics. The area under the receiver operating characteristic curve of each score and their summary receiver operating characteristic curves were calculated with sensitivity and specificity, and the integrated score of the summaries of the receiver operating characteristic curves of all sonographic markers was calculated. Forest plots were used to develop the meta-analysis of each sonographic marker and for the integrated sonographic score. RESULTS: Of 1028 articles reviewed, 12 cohorts and 2 case-control studies including 1630 patients screened for placenta accreta spectrum by clinical-ultrasound scores met the eligibility criteria. A diagnosis of placenta accreta spectrum was reported in 602 (36.9%) cases, for which 547 (90.9%) intraoperative findings and/or histopathologic data were described. A wide variation was observed among the studies in reported sensitivities and specificities and in thresholds used for the identification of patients with a high probability of placenta accreta spectrum at birth. The summaries of the areas under the curve of the individual sonographic scores ranged from 0.85 (the lowest) for subplacental hypervascularity to 0.91 for placental location in the lower uterine segment, myometrial thinning, and placental lacunae and 0.95 for the loss of clear zone. Only 4 studies included placental bulging in their sonographic score system, and therefore no meta-analysis for this score was performed. The integrated summary of the areas under the curve was 0.83 (95% confidence interval, 79-0.86). Forest plot analysis revealed integrated sensitivities and specificities of 0.68 (95% confidence interval, 0.53-0.80) and 0.88 (95% confidence interval, 0.68-0.96), respectively. CONCLUSION: Clinical-sonographic score systems can contribute to the prenatal screening of patients at risk of placenta accreta spectrum at birth. Although we included multiple sonographic studies conducted during the mid-pregnancy period, standardized evaluation should be performed not only with strict ultrasound criteria for the placental position, mid third trimester gestational age at examination, and sonographic markers associated with PAS. Numeric sensitivities, specificities, NPVs, PPV, LR-, and LR+ should be recorded prospectively to assess their accuracy in different set-ups and PTP should be verified at delivery. The variables recommended for most predictive screening are: loss of clear zone underneath the placental bed, placentation in the LUS, and placenta lacunae.
引用
- Pekar Zlotin M, Sharabi-Nov A, Meiri H, et al. Clinical-sonographic scores for the screening of placenta accreta spectrum: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 38636601. doi:10.1016/j.ajogmf.2024.101369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。